The Global Self-Monitoring Blood Glucose Monitoring Devices Market was valued at USD 21.6 billion in 2025 and is estimated to grow at a CAGR of 12.4% to reach USD 67.8 billion in 2035.
Market expansion is driven by the rising global burden of diabetes, continuous improvements in glucose monitoring technologies, and increasing government-led awareness programs focused on early diagnosis and disease management. Growing adoption of self-care-based diabetes management is further strengthening demand for home-use monitoring solutions. Technological progress in device accuracy, portability, and connectivity is also enhancing user convenience and compliance. Rising healthcare expenditure and broader access to diagnostic tools are further supporting market penetration across both developed and emerging economies. In addition, increasing lifestyle-related health risks, sedentary habits, and dietary changes are contributing to higher diabetes incidence, thereby reinforcing the need for continuous glucose monitoring. Expanding awareness regarding preventive healthcare and early intervention is also encouraging patients to adopt self-monitoring solutions for better glycemic control.
The consumables segment was valued at USD 12.1 billion in 2025. Self-monitoring blood glucose monitoring systems rely heavily on consumable products such as test strips and lancets, which are essential for routine glucose testing. These single-use components are widely available through retail channels, ensuring easy access for users managing diabetes at home. Test strips represent a core consumable category as they are designed for single-use blood sample collection and glucose measurement. Their compact and portable nature allows patients to monitor glucose levels conveniently across different settings, including home and workplace environments.
The type 2 diabetes segment held a 69.3% share in 2025. This segment leads due to the widespread nature of type 2 diabetes, where the body either produces insufficient insulin or fails to utilize it effectively, resulting in elevated blood glucose levels. The rising incidence of this condition globally continues to drive sustained demand for regular glucose monitoring, reinforcing segment dominance.
U.S. Self-Monitoring Blood Glucose Monitoring Devices Market reached USD 7.6 billion in 2025. High diabetes-related healthcare expenditure and strong healthcare infrastructure support widespread adoption of advanced monitoring solutions. Continuous investment in innovative diabetes management technologies further strengthens market growth, improving accessibility and patient outcomes across the country.
Key companies operating in the Global Self-Monitoring Blood Glucose Monitoring Devices Market include Roche, Abbott Laboratories, LifeScan, Ascensia Diabetes Care Holdings, Sinocare, B. Braun Melsungen, Sanofi, Arkray, Nova Biomedical, AgaMatrix, DarioHealth, Ypsomed Holding, Bionime Corporation, All Medicus, and Omnis Health. Companies in the self-monitoring blood glucose monitoring devices market are focusing on continuous product innovation to improve accuracy, usability, and connectivity of glucose monitoring systems. Strategic investments in smart and digital health-integrated devices are strengthening real-time data tracking capabilities. Firms are also expanding product portfolios with user-friendly and minimally invasive solutions to enhance patient comfort and adherence. Partnerships with healthcare providers and digital health platforms are improving distribution reach and patient engagement. Increasing emphasis on affordability and accessibility is helping companies penetrate emerging markets.
This product will be delivered within 2-4 business days.
Market expansion is driven by the rising global burden of diabetes, continuous improvements in glucose monitoring technologies, and increasing government-led awareness programs focused on early diagnosis and disease management. Growing adoption of self-care-based diabetes management is further strengthening demand for home-use monitoring solutions. Technological progress in device accuracy, portability, and connectivity is also enhancing user convenience and compliance. Rising healthcare expenditure and broader access to diagnostic tools are further supporting market penetration across both developed and emerging economies. In addition, increasing lifestyle-related health risks, sedentary habits, and dietary changes are contributing to higher diabetes incidence, thereby reinforcing the need for continuous glucose monitoring. Expanding awareness regarding preventive healthcare and early intervention is also encouraging patients to adopt self-monitoring solutions for better glycemic control.
The consumables segment was valued at USD 12.1 billion in 2025. Self-monitoring blood glucose monitoring systems rely heavily on consumable products such as test strips and lancets, which are essential for routine glucose testing. These single-use components are widely available through retail channels, ensuring easy access for users managing diabetes at home. Test strips represent a core consumable category as they are designed for single-use blood sample collection and glucose measurement. Their compact and portable nature allows patients to monitor glucose levels conveniently across different settings, including home and workplace environments.
The type 2 diabetes segment held a 69.3% share in 2025. This segment leads due to the widespread nature of type 2 diabetes, where the body either produces insufficient insulin or fails to utilize it effectively, resulting in elevated blood glucose levels. The rising incidence of this condition globally continues to drive sustained demand for regular glucose monitoring, reinforcing segment dominance.
U.S. Self-Monitoring Blood Glucose Monitoring Devices Market reached USD 7.6 billion in 2025. High diabetes-related healthcare expenditure and strong healthcare infrastructure support widespread adoption of advanced monitoring solutions. Continuous investment in innovative diabetes management technologies further strengthens market growth, improving accessibility and patient outcomes across the country.
Key companies operating in the Global Self-Monitoring Blood Glucose Monitoring Devices Market include Roche, Abbott Laboratories, LifeScan, Ascensia Diabetes Care Holdings, Sinocare, B. Braun Melsungen, Sanofi, Arkray, Nova Biomedical, AgaMatrix, DarioHealth, Ypsomed Holding, Bionime Corporation, All Medicus, and Omnis Health. Companies in the self-monitoring blood glucose monitoring devices market are focusing on continuous product innovation to improve accuracy, usability, and connectivity of glucose monitoring systems. Strategic investments in smart and digital health-integrated devices are strengthening real-time data tracking capabilities. Firms are also expanding product portfolios with user-friendly and minimally invasive solutions to enhance patient comfort and adherence. Partnerships with healthcare providers and digital health platforms are improving distribution reach and patient engagement. Increasing emphasis on affordability and accessibility is helping companies penetrate emerging markets.
Comprehensive Market Analysis and Forecast
- Industry trends, key growth drivers, challenges, future opportunities, and regulatory landscape
- Competitive landscape with Porter’s Five Forces and PESTEL analysis
- Market size, segmentation, and regional forecasts
- In-depth company profiles, business strategies, financial insights, and SWOT analysis
This product will be delivered within 2-4 business days.
Table of Contents
Chapter 1 Methodology and Scope
Chapter 2 Executive Summary
Chapter 3 Industry Insights
Chapter 4 Competitive Landscape, 2025
Chapter 5 Market Estimates and Forecast, by Product, 2022-2035 ($ Mn)
Chapter 6 Market Estimates and Forecast, by Application, 2022-2035 ($ Mn)
Chapter 7 Market Estimates and Forecast, by End Use, 2022-2035 ($ Mn)
Chapter 8 Market Estimates and Forecast, by Region, 2022-2035 ($ Mn)
Chapter 9 Company Profiles
Companies Mentioned
The companies profiled in this Self-Monitoring Blood Glucose Monitoring Devices market report include:- Abbott Laboratories
- AgaMatrix
- All Medicus
- Arkray
- Ascensia Diabetes Care Holdings
- B. Braun Melsungen
- Bionime Corporation
- DarioHealth
- F. Hoffmann-La Roche
- LifeScan
- Nova Biomedical
- Omnis Health
- Sanofi
- Sinocare
- Ypsomed Holding
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 150 |
| Published | April 2026 |
| Forecast Period | 2025 - 2035 |
| Estimated Market Value ( USD | $ 21.6 Billion |
| Forecasted Market Value ( USD | $ 67.8 Billion |
| Compound Annual Growth Rate | 12.4% |
| Regions Covered | Global |
| No. of Companies Mentioned | 15 |
